Supplementary Table 7 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
Publication
, Other
Munster, P; Iannotti, N; Cho, DC; Kirkwood, JM; Villaruz, LC; Gibney, GT; Hodi, FS; Mettu, NB; Jones, M; Bowman, J; Smith, M; O'Day, S ...
December 19, 2023
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Munster, P., Iannotti, N., Cho, D. C., Kirkwood, J. M., Villaruz, L. C., Gibney, G. T., … O’Day, S. (2023). Supplementary Table 7 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. https://doi.org/10.1158/2767-9764.24866726.v1
Munster, Pamela, Nicholas Iannotti, Daniel C. Cho, John M. Kirkwood, Liza C. Villaruz, Geoffrey T. Gibney, F Stephen Hodi, et al. “Supplementary Table 7 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study,” December 19, 2023. https://doi.org/10.1158/2767-9764.24866726.v1.
Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, et al. Supplementary Table 7 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. 2023.
Munster, Pamela, et al. Supplementary Table 7 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. 19 Dec. 2023. Crossref, doi:10.1158/2767-9764.24866726.v1.
Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O’Day S. Supplementary Table 7 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. 2023.